| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TAE684 | CCLE | pan-cancer | AAC | 0.0085 | 0.9 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.0082 | 0.9 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | 0.25 | 5e-14 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.22 | 4e-13 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.2 | 1e-10 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.19 | 7e-10 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | 0.19 | 9e-10 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | 0.19 | 1e-09 |